![Kevin V. Sullivan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kevin V. Sullivan
Director/Miembro de la Junta en Qing Bile Therapeutics, Inc. .
Perfil
Kevin V.
Sullivan is a professional with experience in the biotech industry.
He is currently a Director at Qing Bile Therapeutics, Inc. His former positions include Chief Executive Officer at DeNovaMed, Inc., Chief Executive Officer & Director at Appili Therapeutics, Inc., and Chief Operating Officer at Viron Therapeutics, Inc. Sullivan holds an MBA from the Richard Ivey School of Business.
Cargos activos de Kevin V. Sullivan
Empresas | Cargo | Inicio |
---|---|---|
Qing Bile Therapeutics, Inc. | Director/Miembro de la Junta | 01/05/2015 |
Antiguos cargos conocidos de Kevin V. Sullivan.
Empresas | Cargo | Fin |
---|---|---|
APPILI THERAPEUTICS INC. | Director Ejecutivo | 02/12/2019 |
DeNovaMed, Inc.
![]() DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | Director Ejecutivo | 01/04/2015 |
Viron Therapeutics, Inc.
![]() Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Director de Operaciones | 01/05/2013 |
Formación de Kevin V. Sullivan.
Richard Ivey School of Business | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
APPILI THERAPEUTICS INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Viron Therapeutics, Inc.
![]() Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
DeNovaMed, Inc.
![]() DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | Health Technology |
Qing Bile Therapeutics, Inc. |
- Bolsa de valores
- Insiders
- Kevin V. Sullivan